Degarelix Evidence Guide
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.
Our Take
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.
- Best for
- Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 240mg subcutaneous (two 120mg injections) loading dose, then 80mg subcutaneous monthly
Benefits and Evidence
- Testosterone Suppression: Level A, includes human evidence - Rapidly achieves and maintains castrate testosterone levels (<50 ng/dL) in >98% of patients. Faster onset than GnRH agonists without initial testosterone flare.
- Prostate Cancer Control: Level A, includes human evidence - Phase 3 trials demonstrate non-inferiority to leuprolide for testosterone suppression and PSA reduction in advanced prostate cancer patients.
- Cardiovascular Events: Level B, includes human evidence - Some evidence suggests lower cardiovascular event rates compared to GnRH agonists, particularly in patients with pre-existing cardiovascular disease.
Side Effects and Warnings
- Injection site reactions (pain, erythema, swelling)
- Hot flashes
- Weight gain
- Fatigue
- Increased liver enzymes
- Injection site reactions occur in ~40% of patients
- QT prolongation possible - monitor ECG in at-risk patients
- Hyperglycemia and diabetes risk with long-term androgen deprivation
Research Dosage References
- <strong>Subcutaneous injection</strong> - 240 mg (loading dose) - Once (first dose) - Loading dose administered as two 120 mg injections at different abdominal sites.
- <strong>Subcutaneous injection</strong> - 80 mg - Every 28 days (maintenance) - Maintenance dosing begins 28 days after loading dose. Administered in the abdominal area.
Mechanism of Action
Degarelix works through competitive antagonism of GnRH receptors: 1. GnRH receptor blockade: Binds competitively to pituitary GnRH receptors, preventing endogenous GnRH from activating them. 2. Immediate LH/FSH suppression: Rapidly decreases luteinizing hormone and follicle-stimulating hormone without the initial surge (flare) seen with GnRH agonists. 3. Testosterone suppression: Achieves castrate levels of testosterone within 1-3 days of first injection. 4. PSA reduction: Leads to rapid decline in prostate-specific antigen levels, reflecting reduced tumor stimulation.
Legal Status
FDA-approved for the treatment of advanced prostate cancer. Available by prescription only. Marketed as Firmagon by Ferring Pharmaceuticals.